Cellulite Candidate Shows Promise in Phase IIa Trial

August 21, 2014 1:50 PM

9 0

Cellulite Candidate Shows Promise in Phase IIa Trial

Auxilium Pharmaceuticals announced positive results from a Phase IIa study of collagenase clostridium histolyticum (or CCH) for the treatment of cellulite, or edematous fibrosclerotic panniculopathy. According to the firm, all three doses of CCH (low [0.06 mg], mid [0.48 mg], and high [0.84 mg]) improved the appearance of cellulite as measured by the trial endpoints of an investigator and a patient score on an adapted version of the Global Aesthetic Improvement Scale (GAIS).

The mid- and high-dose groups in particular showed a statistically significant improvement in the appearance of cellulite, with a p-value of <0.05 compared to placebo for both endpoints. Sixty-eight percent of patients in those groups reported being "satisfied" or "very satisfied" with the results o...

Read more

To category page